PTU - Polskie Towarzystwo Urologiczne
home page
current numbers
archival numbers
list of articles:
list przewodni/covering letter
editor
Scientific Committee
publisher
subscription
advertising
important links

Urological literature review: October 2003 - October 2004. Part I
Article published in Urologia Polska 2005/58/1.

authors

Andrzej Borkowski, Tomasz Borkowski
Klinika Urologii Akademii Medycznej w Warszawie
Kierownik kliniki: prof. dr hab. Andrzej Borkowski

references

  1. Saidi A, Descotes J-L, Singel Ch et al: Prise en charge des traumatismes fermes du rein. Prog Urol 2004; 14: 461-471.
  2. Tazi H, Ouali M, Lrhorfi S et al: Le realignement endoscopique dnas la rupture post-traumatique de l´uretre posterieur. Prog Urol 2003; 13: 1345-1350.
  3. Lang EK, Thomas R, Davis R et al: Multiphasic helical computerised tomography for the assessment of microscopic hematuria: a prospective study. J Urol 2004; 171: 237-243.
  4. Spencer JA, Chahal R, Kelly A et al: Evaluation of painful hydronephrosis in pregnancy: magnetic resonance urographic patterns in physiological dilatation versus calculous obstruction. J Urol 2004; 171: 256-260.
  5. Kommu S, Sharifi R, Edwards S et al: Proteomics and urine analysis: a potential promising new tool in urology. Br J Urol Int 2004; 93: 1172-1173.
  6. Ribal MJ, Alcaraz A, Mengual L et al: Chromosomal high-polysomies predict tumor progression in T1 transitional cell carcinoma of the bladder. Ribal MJ, Alcaraz A, Mengual L et al: Eur Urol 2004; 45: 593-599.
  7. Shariat SF, Casella R, Khoddami SM et al: Urine detection of Survivin is a sensitive marker for the noninvasive diagnosis of bladder cancer. J Urol 2004; 171: 626-630.
  8. Ku JH, Kwak Ch, Lee HS et al: Expression of Survivin a novel inhibitor of apoptosis, In superficial transitional cell carcinoma of the bladder. J Urol 2004; 171: 631-635.
  9. Kamat AM, Lamm DL: Antitumor activity of common antibiotics against superficial bladder cancer. Urology 2004; 63: 457-460.
  10. Van der Heijden AG, Kiemeney LA, Gofrit ON et al: Preliminary European results of local microwave hyperthermia and chemotherapy treatment in intermediate or high risk superficial transitional cell carcinoma of the bladder. Eur Urol 2004; 46: 65-72.
  11. Colombo R, Da Pozzo LF, Salonia A et al: Multicentric study comparing intravesical chemotherapy alone and with local microwave hypethermia for prophylaxis of reccurence of superficial transitional cell carcinoma. J Clin Oncol 2003; 21: 4270-4276.
  12. Lamm DL: Intravesical therapy for superficial bladder cancer: slow but steady progress. Editorial. J Clin Oncol 2003; 21: 4259-4260.
  13. Schrier BPh, Hollander MP, van Rhijn BWG et al: Prognosis of muscle-invasive bladder cancer: difference between primary and progressive tumours and implications for therapy. Eur Urol 2004; 45: 292-296.
  14. Ouek ML, Stein JP, Clark PE et al: Natural history of surgically treated bladder carcinoma with extravesical tumor extension. Cancer 2003; 98: 955-961.
  15. Slaton JW, Millikan R, Inoue K et al: Correlation of metastasis related gene expression and relapse-free survival in patients with locally advanced bladder cancer treated with cystectomy and chemotherapy. J Urol 2004; 171: 570-574.
  16. Grossman HB, Natale RB, Tangen CM et al: Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 2003; 349: 859-866.
  17. Eapen L, Stewart D, Collins J et al: Effective bladder sparing therapy with intra-arterial cisplatin and radiotherapy for localized bladder cancer. J Urol 2004; 172: 1276-1280.
  18. Sebe PH, Taxer O, Cussenot O et al: Cystectomie avec conservation prostatique dans le traitement des tumeurs de vessie: bases anatomiques, techniques chirurgicales, indications et resultats. Progres en Urologie 2003; 13: 1279-1285.
  19. Master VA, Meng MV, Grossefeld GD et al: Treatment and outcome of invasive bladder cancer in patients after renal transplantation. J Urol 2004; 171: 1085-1088.
  20. Wehle MJ, Thiel DD, Petrou SP et al: Conservative management of incidental contrast-enhancing renal masses as a safe alternative to invasive therapy. Urology 2004; 64: 49-52.
  21. Volpe A, Panzarella T, Rendon RA et al: The natural history of incidentally detected small renal masses. Cancer 2004; 100: 738-745.
  22. Duffey BG, Choyke PL, Glenn G et al: The relationship between renal tumor size and metastases in patients with von Hippel-Lindau disease. J Urol 2004; 172: 63-65.
  23. Lang H, Lindner V, Martin M et al: Prognostic value of multifocality on progression and survival in localized renal cell carcinoma. Eur Urol 2004; 45: 749-753.
  24. Kamat AM, Shock RP, Naya Y et al: Prognostic value of body mass index in patients undergoing nephrectomy for localized renal tumors. Urology 2004; 63: 46-50.
  25. Patard E-J, Shvarts O, Lam JS et al: Safety and efficacy of partia nephrectomy for all T1 tumors based on an international multicenter experience. J Urol 2004; 171: 2181-2185.
  26. DJ, Clark PE, Assimos DG et al: Utility of frozen section analysis of resection margins during partial nephrectomy. Urology 2004; 64: 31-34.
  27. Bhayani SA, Rha KH, Pinto PA et al: Laparoscopic partial nephrectomy: effect of warm ischemia on serum creatinine. J Urol 2004; 172: 1264-1266.
  28. Flanigan JC, Mickisch G, Sylvester R et al: Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J Urol 2004; 171: 1071-1076.
  29. Leibovich BC, Han K-R, Bui MHT et al: Scoring algorithm to predict survival after nephrectomy and immunotherapy in patients with metastatic renal cell carcinoma. Cancer 2003; 98: 2566-2575.
  30. Wu F, Wang Z-B, Chen W-Z et al: Preleminary experience using high intensity focused ultrasound for the treatment of patients with advaced stage renal malignancy. J Urol 2003; 170: 2237-2240.
  31. Lipton A, Zheng M, Seaman J: Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinoma. Cancer 2003; 98: 962-969.
  32. Oldenburg J, Alfsen GC, Lien HH et al: Postchemotherapy retroperitoneal surgery remains necessary in patients with nonseminomatous testicular cancer and minimal residual tumor masses. J Clin Oncol 2003; 21: 3310-3317.
  33. Stamey TA, Caldwell M, McNeal JE et al: The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years. J Urol 2004; 172: 1297-1301.
  34. Tinzl M, Marberger M, Horvath S et al: DD3PCA3 RNA analysis in urine-a new perspective for detecting prostate cancer. Eur Urol 2004; 46: 182-187.
  35. Fradet Y, Saad F, Aprikian A et al: uPM3 a new molecular urine test for the detection of prostate cancer. Urology 2004; 64: 311-316.
  36. Dhir R, Vietmeier B, Arlotti J et al: Early identification of individuals with prostate cancer in negative biopsies. J Urol 2004; 171: 1419-1423.
  37. Kattan MW, Eastham JA, Wheeler TM et al: Counseling men with prostate cancer: a nomogram for predicting the presence of small, moderately differentiated, confined tumors. J Urol 2003; 170: 1792-1797.
  38. Patel MI, DeConcini DT, Lopez-Corona E et al: An analysis of man with clinically localized prostate cancer who deffered definitive therapy. J Urol 2004; 171: 1520-1524.
  39. Ohori M, Kattan MW, Koh H et al: Predicting the presence and side of extracapsular extension: a nomogram for staging prostate cancer. J Urol 2004; 171: 1844-1849.
  40. Lepor H, Kaci L: Role of intraoperative biopsies during radical retropubic prostatectomy. Urology 2004; 63: 499-502.
  41. Zwergel U, Lehmann J, Wullich B et al: Lymph node positive prostate cancer: long-term survival data after radical prostatectomy. J Urol 2004; 171: 1128-1131.
  42. Lepor H, Kaci L: The impact of open radical retropubic prostatectomy on continence and lower urinary tract symptoms: a prospective assessemantusing validated self-administered outcome instruments. J Urol 2004; 171: 1216-1219.
  43. Kumar V, Toussi H, Marr C et al: The benefit of radical prostatectomy beyond cancer control in symptomatic men with prostate cancer. Br J Urol Int 2004; 93: 507-509.
  44. Miller NL, Theodorescu D: Haelth-related quality of life after prostate brachytherapy. BJU International 2004; 94: 487-491.
  45. Jani AB, Kao J, Hellman S: Hormone therapy adjuvant to external beam radiotherapy for locally advanced prostate carcinoma. Cancer 2003; 98: 2351-2361.
  46. Van Vulpen M, De Leeuw AAC, Raaymakers RJA et al: Radiotherapy and hypertermia in the treatment of patients with locally advanced prostate cancer: preliminary results. Br J Urol Int 2004; 93: 36-41.
  47. Jacob R, Hanlon AL, Horwitz EM et al: The relationship of increasing radiotherapy dose to reduced distant metastases and mortality in men with prostate cancer. Cancer 2004; 100: 538-543.
  48. Thurairaja R, McFarlane J, Traill Z et al: State-of-the-art approaches to detecting early bone metastasis in prostate cancer. BJU International 2004; 94: 268-271.
  49. Kelly WK, Steineck G: Bisphosphonates for men with prostate cancer: sifting through the rubble. J Clin Oncol 2003; 21: 4261-4262.
  50. Sieber PR, Keiller DR, Kahnoski RJ et al: Bicalutamide 150 mg maintains bone mineral density during monotherapy for localised or locally advanced prostate cancer. J Urol 2004; 171: 2272-2276.
  51. Klotz L, Schellhammer P, Carroll K: A re-assessemsnt of the role of combined androgen blockade for advanced prostate cancer. BJU International 2004; 93: 1177-1182.
  52. Pruthi RS, Derksen JE, Moore D: A pilot study of use of the cyclooxygenase-2 inhibitor celecoxib in reccurent prostate cancer after definitive radiation therapy or radical prostatectomy. BJU International 2004; 93: 275-278.
  53. Damber JE. Decreasing mortality rates for prostate cancer: posible role of hormonal therapy? Br J Urol Int 2004; 93: 695-701.
  54. Pether M, Goldenberg SL: Intermittent androgen supresion. BJU International 2004; 93: 258-261.
  55. Moul JW, Wu H, Sun L et al: Early versus delayed hormonal therapy for prostate specific antygen only recurrence of prostate cancer after radical prostatectomy. J Urol 2004; 171: 1141-1147.
  56. Scherr DS, Pitts WR jr: The nonsteroidal effects of diethylstilbestrol: the rationale for androgen deprivation therapy without estrogen deprivation in the treatment of prostate cancer. J Urol 2003; 170: 1703-1708.
  57. Corcoran NM, Najdovska M, Costello AJ: Inorganic selenium retards progression of experimental hormone refractory prostate cancer. J Urol 2004; 171: 907-910.
  58. Khan MA, Carducci MA, Partin AW: The evolving role of docetaxel in the management of androgen independent prostate cancer. J Urol 2003; 170: 1709-1716.
  59. Van der Poel HG: Smart drugs in prostate cancer. Eur Urol 2004; 45: 1-17.

correspondence

Andrzej Borkowski
Klinika Urologii AM
ul. Lindleya 4
02-005 Warszawa
tel. (0... 22) 502 17 23
urolwa@warman.com.pl